Afzeta (Afatinib Dimaleate) Tablet

Description

Description

This page contains brief details about the drug afatinib dimaleate, it’s indication, dosage & administaration, mechanism of action, related brands with strength, warnings and common side effects.

Date of Approval

Afatinib Dimaleate is an anticancer medicine was approved by the US Food and Drug Administration (FDA) on July 12, 2013, to treat patients with non-small cell lung cancer (NSCLC) whose tumors have certain (non-resistant) abnormal epidermal growth factor receptor (EGFR) genes and patients with metastatic, squamous NSCLC progressing after platinum-based chemotherapy.

Mechanism of Action of Afatinib Dimaleate

It functions by inhibiting the ErbB family of proteins, which includes EGFR (also known as the epidermal growth factor receptor, or ErbB1, ErbB2, ErbB3, and ErbB4) and HER2. Changes in the genes that create these proteins can have an impact on how cancer cells multiply and disseminate. Through the inhibition of these proteins and its activities, this medication can prevent the growth and proliferation of cancer cells and can help to slow or stop the progression of cancer.

Uses of Afatinib Dimaleate

Afatinib dimaleate is used to treat certain types of cancer, including non-small cell lung cancer with specific EGFR mutations.

Afatinib Dimaleate Dosage available

Afatinib dimaleate is an oral medication that is usually taken once a day, at approximately the same time each day, before food. If you have already eaten, wait at least 3 hours before taking this medicine.

It should be taken as prescribed by a doctor. These tablets should be swallowed whole with a glass of water. They should not be crushed, chewed, or opened, as this can affect how the medication is absorbed and decrease its effectiveness. Take the missed dose as soon as you recall if your next planned dose is more than eight hours away. You should not take a double dose to make up for the second dose.